These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34854196)

  • 21. Management of immune checkpoint inhibitor-induced bullous pemphigoid.
    Apalla Z; Lallas A; Delli F; Lazaridou E; Papalampou S; Apostolidou S; Gerochristou M; Rigopoulos D; Stratigos A; Nikolaou V
    J Am Acad Dermatol; 2021 Feb; 84(2):540-543. PubMed ID: 32428613
    [No Abstract]   [Full Text] [Related]  

  • 22. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bullous pemphigoid presenting as generalized pruritus: observations in six patients.
    Alonso-Llamazares J; Rogers RS; Oursler JR; Calobrisi SD
    Int J Dermatol; 1998 Jul; 37(7):508-14. PubMed ID: 9679691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.
    Abdat R; Waldman RA; de Bedout V; Czernik A; Mcleod M; King B; Gordon S; Ahmed R; Nichols A; Rothe M; Rosmarin D
    J Am Acad Dermatol; 2020 Jul; 83(1):46-52. PubMed ID: 32179082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid.
    Xiao Y; Gu Y; Xia D; Zhou X; Li W
    J Dermatol; 2023 Feb; 50(2):e76-e78. PubMed ID: 36028948
    [No Abstract]   [Full Text] [Related]  

  • 26. Non-pruritic bullous scabies in an immunosuppressed pediatric patient.
    Salame N; Holland V
    Pediatr Dermatol; 2019 Jul; 36(4):552-553. PubMed ID: 30989695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab as a novel therapy for bullous pemphigoid.
    Zhang X; Man X; Tang Z; Dai R; Shen Y
    Int J Dermatol; 2023 Apr; 62(4):e263-e266. PubMed ID: 36440691
    [No Abstract]   [Full Text] [Related]  

  • 28. Pruritogens in pemphigoid diseases: Possible therapeutic targets for a burdensome symptom.
    Hiroyasu S; Barit JJG; Hiroyasu A; Tsuruta D
    J Dermatol; 2023 Feb; 50(2):150-161. PubMed ID: 36477831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hickam versus Ockham: atopic dermatitis and bullous pemphigoid or pemphigoid nodularis? Dupilumab solves the problem.
    Mutton T; Bocchi C; Gaban A; Marzola E; Schettini N; Borghi A
    Ital J Dermatol Venerol; 2024 Jun; 159(3):361-363. PubMed ID: 38695597
    [No Abstract]   [Full Text] [Related]  

  • 30. Bullous pemphigoid successfully treated with dupilumab.
    Martinez DAES; Periquito AFS; Roa GG; Lupi JP; Treu CM; Lupi O
    An Bras Dermatol; 2024; 99(5):778-780. PubMed ID: 38876965
    [No Abstract]   [Full Text] [Related]  

  • 31. Dupilumab treatment for cholestatic pruritus.
    Chovatiya R; Brieva J; Hung A
    Dermatol Ther; 2022 Mar; 35(3):e15296. PubMed ID: 34981593
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.
    Wang SH; Shan Y; Li SZ; Zuo YG
    Front Immunol; 2023; 14():1165106. PubMed ID: 37545503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China.
    Qi W; Rushan X
    Int Immunopharmacol; 2023 May; 118():110050. PubMed ID: 37003187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis.
    Lu L; Yu Y; Zhang J; Fan X; Qi Y; Lin B
    J Dermatol; 2022 Jan; 49(1):e13-e15. PubMed ID: 34633684
    [No Abstract]   [Full Text] [Related]  

  • 35. Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
    Wang SH; Zuo YG
    Front Immunol; 2021; 12():800609. PubMed ID: 34887875
    [No Abstract]   [Full Text] [Related]  

  • 36. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review.
    Liang J; Abulikemu K; Maolidan ; Hu F; Zhao J; Qiu Y; Wang Q; Sang Y; Hong Y; Kang X
    Int Immunopharmacol; 2023 Mar; 116():109788. PubMed ID: 36731156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
    Hendricks AJ; Yosipovitch G; Shi VY
    J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
    [No Abstract]   [Full Text] [Related]  

  • 38. A perplexing case of pruritic plaques. Bullous pemphigoid.
    Hsu S
    Postgrad Med; 2000 Feb; 107(2):231-2. PubMed ID: 10689419
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.
    Huang D; Zhang Y; Yu Y; Jiang Y; Kong L; Ding Y; Shi Y; Gao Y
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111157. PubMed ID: 37925949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non-bullous pemphigoid.
    Ben Mordehai Y; Faibish H; Astman N; Greenberger S; Barzilai A; Baum S
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):161-165. PubMed ID: 31423677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.